Skip to main content
Kukje Pharma Co., Ltd. logo

Kukje Pharma Co., Ltd. — Investor Relations & Filings

Ticker · 002720 ISIN · KR7002720001 KO Manufacturing
Filings indexed 299 across all filing types
Latest filing 2019-11-12 Major Shareholding Noti…
Country KR South Korea
Listing KO 002720

About Kukje Pharma Co., Ltd.

https://www.kukjepharm.co.kr/index.php?…

Kukje Pharma Co., Ltd. is a company engaged in the manufacturing, distribution, import, and export of pharmaceutical products, cosmetics, and health supplements. Its core offerings include a wide range of prescription (ETC) and over-the-counter (OTC) drugs, with a notable specialization in antibiotics such as Cephalosporins. In addition to its primary pharmaceutical business, the company also develops and markets cosmetic products, food supplements, and respiratory protection face masks. The company serves both domestic and international markets.

Recent filings

Filing Released Lang Actions
주식등의대량보유상황보고서(일반)
Major Shareholding Notification Classification · 100% confidence The document is a '주식등의 대량보유상황보고서' (Report on Large Shareholding), which is a standard regulatory filing in South Korea under the Capital Markets Act. It details changes in share ownership by major shareholders and special related parties, including specific transaction dates, methods (e.g., open market purchases), and share counts. This type of filing is specifically categorized as a 'Major Shareholding Notification' (MRQ) in the provided schema.
2019-11-12 Korean
임원ㆍ주요주주특정증권등소유상황보고서
Director's Dealing Classification · 100% confidence The document is a Korean regulatory filing titled '임원ㆍ주요주주 특정증권등 소유상황보고서' (Report on Ownership of Specific Securities by Executives and Major Shareholders). This is a standard disclosure form used in South Korea for reporting insider transactions (director's dealings). It details the share ownership changes of an executive (Ahn Seok-hwan) at Kukje Pharma. This fits the 'Director's Dealing' category.
2019-10-29 Korean
임원ㆍ주요주주특정증권등소유상황보고서
Director's Dealing Classification · 100% confidence The document is titled '임원ㆍ주요주주 특정증권등 소유상황보고서' (Report on Ownership of Specific Securities by Executives and Major Shareholders). It details the share transactions (specifically '장내매수' or open market purchase) by an executive (Ahn Seok-hwan) of Kukje Pharma. This type of filing is a standard regulatory requirement for insider trading/shareholding disclosures, which corresponds to the 'Director's Dealing' category.
2019-09-27 Korean
임원ㆍ주요주주특정증권등소유상황보고서
Director's Dealing Classification · 100% confidence The document is titled '임원ㆍ주요주주 특정증권등 소유상황보고서' (Report on Ownership of Specific Securities by Executives and Major Shareholders). It details the share acquisition (장내매수) by an executive (안석환) of Kukje Pharma. This is a standard regulatory filing for insider trading/director dealings in the Korean market, which corresponds to the 'Director's Dealing' category.
2019-08-27 Korean
반기보고서 (2019.06)
Interim / Quarterly Report Classification · 100% confidence The document is a '반기보고서' (Semi-annual Report) for Kukje Pharma Co., Ltd. for the period ending June 30, 2019. It contains comprehensive financial data, business operations, and management analysis, which fits the definition of an Interim/Quarterly Report (IR). H1 2019
2019-08-14 Korean
임원ㆍ주요주주특정증권등소유상황보고서
Director's Dealing Classification · 100% confidence The document is a Korean regulatory filing titled '임원ㆍ주요주주 특정증권등 소유상황보고서' (Report on Ownership of Specific Securities by Executives and Major Shareholders). This is a standard disclosure form used in South Korea (often filed with the Financial Supervisory Service) to report insider trading or changes in shareholdings by company directors and major shareholders. Based on the provided definitions, this falls under 'Director's Dealing' (DIRS), which covers personal share transactions by company directors and executives.
2019-08-08 Korean

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.